• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Vaccine . Adjuvant-free pH-controlled aggregates of E. coli-expressed H1N1-RBD enhance neutralizing antibody responses and confer protection against

tetano

Editor, Senior Moderator
Vaccine

Thao Tu[SUP] 1 [/SUP], Ching-Yu Tseng[SUP] 2 [/SUP], Md Din Islam[SUP] 1 [/SUP], Wei-Li Hsu[SUP] 3 [/SUP], Shan-Chia Ou[SUP] 2 [/SUP], Toshio Yamazaki[SUP] 4 [/SUP], Chung-Ping Huang[SUP] 2 [/SUP], Yu-Chen Hsu[SUP] 2 [/SUP], Yutaka Kuroda[SUP] 5 [/SUP]


Affiliations
Abstract

In this study, we used the E. coli-expressed recombinant influenza H1N1 receptor-binding domain (H1N1-RBD; MW = 27.4 kDa) as a model to explore how stable oligomers or aggregates can be produced by modulating sample conditions (temperature and pH), and to examine whether such colloidal/conformational modulations enhance immunogenicity toward vaccine antigen design. We thus analyzed the biophysical properties of the protein under three different pHs at 25 °C and 37 °C using DLS, SLS, CD, and tryptophan fluorescence spectroscopy, and analyzed the immune response in mice. We found that the E. coli-expressed H1N1-RBD was predominantly monomeric at pH 4.7, oligomerized at pH 6.0 (R[SUB]h[/SUB] ∼ 20 nm), and formed large aggregates (R[SUB]h[/SUB] < 1000 nm) at pH 7.4. Immunization studies in Jcl:ICR and BALB/c mice revealed that the oligomeric form (pH 6.0) elicited the highest IgG titers, whereas the monomeric (pH 4.7) and the aggregated (pH 7.4) forms induced weaker antibody responses. Despite this, all three preparations generated neutralizing antisera, with neutralization potency increasing in the order oligomers < monomers < aggregates, in the absence of adjuvants. Notably, the aggregated H1N1-RBD conferred protection against live viral challenge comparable to that of an inactivated influenza vaccine, as demonstrated by plaque reduction assays in MDCK cells and in vivo challenge experiments in BALB/c mice. Flow cytometric analysis further revealed robust long-term immune memory, with central memory CD4[SUP]+[/SUP] T cells accounting for 52.53-65.04% and CD8[SUP]+[/SUP] T cells for 23.81-37.85% of the population. Overall, our findings highlight the potential of E. coli-produced proteins as vaccine antigens and suggest that pH-controlled protein oligomerization/aggregation can significantly boost immunogenicity and the neutralizing efficiency of antisera.

Keywords: H1N1; Influenza A; Neutralizing antibodies; Receptor-binding domain; pH-controlled aggregation, immunogenicity.

 
Back
Top